Prognostic Significance of (18)FDG PET/CT in Colorectal Cancer Patients with Liver Metastases: a Meta-analysis

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2015 Nov 22

PMID 26589835

Citations 28

Authors

Qian Xia

Jianjun Liu

Cheng Wu

Shaoli Song

Linjun Tong

Gang Huang

Yuanbo Feng

YanSheng Jiang

Yewei Liu

Ting Yin

Yicheng Ni

Affiliations

Soon will be listed here.

Abstract

Background: The role of 18-fluorodeoxyglucose positron emission tomography CT ((18)FDG PET/CT), as a prognostic factor for survival in colorectal cancer patients with liver metastases, is still controversial. We sought to perform a meta-analysis of the literature to address this issue.

Methods: A systematic literature search was performed to identify the studies that associated (18)FDG PET/CT to clinical survival outcomes of patients with liver metastases. Methodological qualities of the included studies were also assessed. The summarized hazard ratio (HR) was estimated by using fixed- or random-effect model according to heterogeneity between trails.

Results: By analyzing a total of 867 patients from 15 studies, we found that PET/CT for metabolic response to the therapy was capable of predicting event-free survival (EFS) and overall survival (OS) with statistical significance, and the HR was 0.45 (95% confidence interval [CI], 0.26-0.78) and 0.36 (95% CI, 0.18-0.71), respectively. Furthermore, pre-treatment (18)FDG PET/CT with high standardized uptake value (SUV) was also significantly associated with poorer OS HR, 1.24; (95% CI, 1.06-1.45). However, we did not find a statistically significant effect of post-treatment SUV for predicting OS HR, 1.68; (95% CI, 0.63-4.52).

Conclusions: The present meta-analysis confirms that (18)FDG PET/CT is a useful tool to help predict survival outcomes in patients with liver metastases.

Citing Articles

The prognostic utility of F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis.

Al-Ibraheem A, Abdlkadir A, Al-Adhami D, Sathekge M, Bom H, Makoseh M Front Immunol. 2024; 15:1424269.

PMID: 39286245 PMC: 11402741. DOI: 10.3389/fimmu.2024.1424269.

History of liver surgery.

Banerjee A, Hariharan D Clin Liver Dis (Hoboken). 2024; 23(1):e0237.

PMID: 38919867 PMC: 11199012. DOI: 10.1097/CLD.0000000000000237.

Advances and prospects in deuterium metabolic imaging (DMI): a systematic review of in vivo studies.

Pan F, Liu X, Wan J, Guo Y, Sun P, Zhang X Eur Radiol Exp. 2024; 8(1):65.

PMID: 38825658 PMC: 11144684. DOI: 10.1186/s41747-024-00464-y.

Comprehensive literature review of oral and intravenous contrast-enhanced PET/CT: a step forward?.

Metrard G, Cohen C, Bailly M Front Med (Lausanne). 2024; 11:1373260.

PMID: 38566921 PMC: 10985176. DOI: 10.3389/fmed.2024.1373260.

Detection of Liver Lesions in Colorectal Cancer Patients Using F-FDG PET/CT Dual-Time-Point Scan Imaging.

Boanova L, Altmayer S, Watte G, Raupp A, Francisco M, Strieder de Oliveira G Cancers (Basel). 2023; 15(22).

PMID: 38001662 PMC: 10670707. DOI: 10.3390/cancers15225403.

References

Lee H, Kim H, Hong Y, Kim T, Kim J, Yu C . Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J Nucl Med. 2014; 55(4):582-9. DOI: 10.2967/jnumed.113.128629. View

de Geus-Oei L, van Laarhoven H, Visser E, Hermsen R, van Hoorn B, Kamm Y . Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2007; 19(2):348-52. DOI: 10.1093/annonc/mdm470. View

Kostakoglu L, Coleman M, Leonard J, Kuji I, Zoe H, Goldsmith S . PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002; 43(8):1018-27. View

Downey R, Akhurst T, Gonen M, Vincent A, Bains M, Larson S . Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004; 22(16):3255-60. DOI: 10.1200/JCO.2004.11.109. View

Aras M, Erdil T, Dane F, Gungor S, Ones T, Dede F . Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun. 2015; 37(1):9-15. DOI: 10.1097/MNM.0000000000000401. View

Vansteenkiste J, Stroobants S, Dupont P, De Leyn P, Verbeken E, Deneffe G . Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999; 17(10):3201-6. DOI: 10.1200/JCO.1999.17.10.3201. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Lastoria S, Piccirillo M, Caraco C, Nasti G, Aloj L, Arrichiello C . Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med. 2013; 54(12):2062-9. DOI: 10.2967/jnumed.113.119909. View

Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L . Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2011; 23(7):1687-93. DOI: 10.1093/annonc/mdr554. View

10.

Wang Y, Zeng T . Response to: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2013; 14:391. PMC: 3842792. DOI: 10.1186/1745-6215-14-391. View

11.

Zhao Q, Feng Y, Mao X, Qie M . Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer: a meta-analysis. Int J Gynecol Cancer. 2013; 23(7):1184-90. DOI: 10.1097/IGC.0b013e31829ee012. View

12.

Haug A, Tiega Donfack B, Trumm C, Zech C, Michl M, Laubender R . 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012; 53(3):371-7. DOI: 10.2967/jnumed.111.096230. View

13.

Fendler W, Philippe Tiega D, Ilhan H, Paprottka P, Heinemann V, Jakobs T . Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013; 54(8):1202-8. DOI: 10.2967/jnumed.112.116426. View

14.

De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J . Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012; 106(12):1926-33. PMC: 3388560. DOI: 10.1038/bjc.2012.184. View

15.

Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C . Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the.... J Thorac Oncol. 2008; 3(1):6-12. DOI: 10.1097/JTO.0b013e31815e6d6b. View

16.

Ott K, Weber W, Lordick F, Becker K, Busch R, Herrmann K . Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006; 24(29):4692-8. DOI: 10.1200/JCO.2006.06.7801. View

17.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371(9617):1007-16. PMC: 2277487. DOI: 10.1016/S0140-6736(08)60455-9. View

18.

Tam H, Cook G, Chau I, Drake B, Zerizer I, Du Y . The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis. Clin Nucl Med. 2015; 40(5):e259-64. DOI: 10.1097/RLU.0000000000000744. View

19.

Minn H, Lapela M, Klemi P, Grenman R, Leskinen S, Lindholm P . Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1998; 38(12):1907-11. View

20.

Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H . Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998; 82(11):2227-34. View